Navigation Links
NeurogesX Closes $25 Million Private Placement
Date:1/9/2008

SAN MATEO, Calif., Jan. 9 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing novel pain management therapies, today announced that it completed a $25.0 million private placement of its common stock to support the development of its late stage portfolio of novel pain management therapies.

On December 26, 2007, the Company announced that on Sunday, December 23, 2007, it entered into a securities purchase agreement in connection with a private placement to a group of institutional accredited investors. In the closings, which occurred on December 26 and January 3, the Company received approximately $25 million in gross proceeds from the sale of 4,020,910 shares of its common stock at a purchase price of $6.18 per share, the last closing price prior to signing of NGSX common stock on the NASDAQ Global Market, and the issuance of five-year warrants to purchase 1,206,273 additional shares of NGSX common stock at an exercise price of $8.034 per share. The warrants were purchased at a price per underlying share of $0.125.

The financing was led by SV Life Sciences, a life sciences-focused venture capital adviser and manager. SV Life Sciences advised or managed funds invest in companies requiring funding within the human life sciences sector including biotechnology and pharmaceuticals, medical devices and instruments, healthcare IT and services. SV Life Sciences advises or manages four venture capital funds and a publicly traded investment trust with total capital of approximately $1.6 billion that invest in life sciences companies at all stages of development. Bruce Peacock, a venture partner at SV Life Sciences, has served as an independent director of NeurogesX, Inc. since August, 2007.

Other participating investors include Deerfield Management and Wasatch Advisors, Inc., and its private equity affiliate, Cross Creek Capital.

Pacific Growth Equities, LLC served as the exclusive placement agent for the transaction.

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements. NeurogesX has agreed to file a registration statement with the Commission covering the resale of the shares of common stock, including shares of common stock issuable upon exercise of the warrants, sold in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX- 4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Three Phase 3 clinical trials with NGX- 4010 have been completed and have met their primary endpoints, two in PHN and one in painful HIV-DSP.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX

Stephen Ghiglieri

(650) 358-3310

sghiglieri@neurogesx.com

The Ruth Group

Investors / Media

Stephanie Carrington / Jason Rando

(646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NeurogesX, Inc. Announces $25 Million Private Placement
2. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
3. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
6. NeurogesX Appoints New Director to the Board
7. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
8. AspenBio Pharma Closes $18.2 Million Private Placement of Common Stock
9. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
10. Helix BioPharma closes $16.9 million private placement of common shares
11. The closest look ever at native human tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... 2016 , ... Meister Media Worldwide launches its new and ... functionality give the agricultural world a taste of Meister Media Worldwide’s full menu ... from precision farming via satellites and Unmanned Aerial Vehicles (UAVs) to indoor farming ...
(Date:4/29/2016)... ... April 29, 2016 , ... Amendia, Inc., a ... procedures, today announced the completion of a significant transaction and partnership that positions ... customers and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private equity ...
(Date:4/29/2016)... Italy , April 29, 2016 ... 5.11, the latest update to its industry-leading treatment planning ... shown that Monaco version 5.11 ... can now attain calculation speeds up to four times ... . With the industry,s gold standard ...
(Date:4/28/2016)... ... April 28, 2016 , ... As part of ... industry experts, and expanding its LATAM network and logistics capabilities. Enhancements have ... manage their clinical trial projects. , The expansion will provide unmatched clinical trial ...
Breaking Biology Technology:
(Date:3/11/2016)... -- http://www.apimages.com ) - --> http://www.apimages.com ) ... AP Images ( http://www.apimages.com ) - Germany ... the new refugee identity cards. DERMALOG will be unveiling this device, ... Hanover next week.   --> Germany ... produce the new refugee identity cards. DERMALOG will be unveiling this ...
(Date:3/9/2016)... , March 9, 2016 ... government identified that more than 23,000 public service employees ... had been receiving their salary unlawfully.    --> ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ...
(Date:3/3/2016)... DE SOTO, Kansas , March 3, 2016 /PRNewswire/ ... offer Oncimmune,s Early CDT®-Lung, a blood test to ... lung cancer Early CDT®-Lung test to its ... --> Early CDT®-Lung test to its clients which ... Oncimmune, a leader in early cancer detection, today announced ...
Breaking Biology News(10 mins):